Edition:
United States

Redhill Biopharma Ltd (RDHL.TA)

RDHL.TA on Tel Aviv Stock Exchange

356.60ILa
29 Mar 2017
Change (% chg)

-- (--)
Prev Close
356.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
392,837
52-wk High
610.30
52-wk Low
337.70

Latest Key Developments (Source: Significant Developments)

Redhill Biopharma says U.S. District court granted Concordia unit treble damages
Tuesday, 7 Mar 2017 08:00am EST 

Redhill Biopharma Ltd : Redhill Biopharma - U.S. District court granted Concordia unit treble damages related to false claims made by Method Pharmaceuticals, LLC, principal owner . Redhill Biopharma - Redhill expects to initiate promotion of Donnatal in Q2 of 2017 . Redhill Biopharma - court awarded Concordia treble damages of $2.2 million, an increase from original damages award of $733,000 .Redhill Biopharma - in Jan, co announced co-promotion agreement with unit of Concordia, granting co certain promotional rights in U.S. for Donnatal.  Full Article

Redhill Biopharma provides 2017 semi-annual business update
Thursday, 12 Jan 2017 06:01am EST 

Redhill Biopharma Ltd : Provides 2017 semi-annual business update . Re-submission of Rizaport NDA to FDA is expected in first half of 2017 .Top-line results are expected in mid-2017 from clinical study with Bekinda.  Full Article

Redhill Biopharma reports qtrly loss per ordinary share $0.07
Monday, 14 Nov 2016 07:10am EST 

Redhill Biopharma Ltd - : Qtrly loss per ordinary share $0.07 .Redhill biopharma reports 2016 third quarter financial results.  Full Article

Redhill Biopharma provides 2016 semi-annual research and development update
Thursday, 11 Aug 2016 09:00am EDT 

Redhill Biopharma : Provides 2016 semi-annual research and development update .Estimated timing for top-line results for Phase II study with Bekinda for IBS-D are anticipated in mid-2017.  Full Article

Redhill Biopharma reports Q2 2016 earnings of $0.06 per share
Tuesday, 26 Jul 2016 07:00am EDT 

Redhill Biopharma Ltd :Quarterly earnings per share $0.06.  Full Article

Redhill Biopharma receives additional U.S. Patent covering RHB-105
Thursday, 21 Jul 2016 10:28am EDT 

: Redhill Biopharma receives additional U.S. patent covering RHB-105 ahead of confirmatory phase III study for H. Pylori infection .Received notice of allowance for additional U.S. Patent covering RHB-105, expected to be valid until 2034 once granted.  Full Article

Redhill Biopharma says announces collaboration with NIH for potential ebola treatment
Wednesday, 13 Jul 2016 07:00am EDT 

Redhill Biopharma Ltd : Redhill biopharma announces research collaboration with nih for potential ebola treatment .If successful, study is intended to provide supportive data for discussions with fda for potential use of animal rule pathway for approval.  Full Article

RedHill Biopharma, IntelGenx announce agreement for commercialization of RIZAPORT
Tuesday, 5 Jul 2016 09:00am EDT 

Redhill Biopharma Ltd : RedHill Biopharma and IntelGenx announce definitive agreement for commercialization of RIZAPORT™ for migraines with Grupo Juste in Spain and additional potential territories . Commercial launch in Spain is expected to take place in second half of 2017 . Initial term of deal is for ten years from date of first commercial sale, shall automatically renew for additional two-year term . Under terms of agreement, RedHill granted Grupo Juste exclusive rights to register and commercialize RIZAPORT in Spain . Co, IntelGenx entitled to also receive tiered royalties . Financial terms of agreement were not disclosed .Co, IntelGenx entitled to receive upfront payment,additional milestone payments upon achievement of predefined regulatory.  Full Article

Redhill Biopharma says drug for Crohn's disease shows potential efficacy in trial
Wednesday, 22 Jun 2016 08:00am EDT 

Redhill Biopharma Announces Publication Demonstrating Potential Efficacy Of Rhb : 104 for crohn's disease associated with map infection . Interim data and safety monitoring board (dsmb) analysis expected in second half of 2016 for rhb-104 .Final results from phase iia proof-of-concept study with rhb-104 in multiple sclerosis are also expected in second half of 2016.  Full Article

Redhill Biopharma says Yeliva met main goal in early-stage study in solid tumors
Tuesday, 21 Jun 2016 08:00am EDT 

Redhill Biopharma Ltd : Redhill biopharma announces positive final results with primary and secondary endpoints met in phase 1 study with yeliva™ in advanced solid tumors . Phase i/ii study with yeliva for refractory or relapsed multiple myeloma is planned to be initiated in coming weeks .Phase ii study with yeliva ™ for treatment of advanced hepatocellular carcinoma is planned to be initiated in q3/2016.  Full Article

More From Around the Web

BRIEF-Redhill biopharma reports first patient dosed in open-label extension study

* Redhill Biopharma announces first patient dosed in the open-label extension study to the phase iii study with rhb-104 for crohn’s disease